Clinical Trials Logo

Clinical Trial Summary

Heart failure with preserved ejection and hypertrophic cardiomyopathy are common diseases and often associated with transthyretin cardiac amyloidosis (TTR-CM), especially in elderly people. Nevertheless, research of TTR-CM is recommended in patients with ventricular hypertrophy without other cause such as valvular disease or hypertension. Therefore, the exact prevalence of TTR-CM remains unknown. We aim to determine the prevalence of TTR-CM in patients with ventricular hypertrophy and aged ≥ 60 years old, hospitalized in our cardiology department (CHU de Poitiers) by performing bone scintigraphy and research of AL amyloidosis.

Clinical Trial Description

Not Provided ;

Study Design

Related Conditions & MeSH terms

NCT number NCT05064839
Study type Interventional
Source Poitiers University Hospital
Contact Claire BOULETI, MD
Phone +33 5 49 44 43 25
Email [email protected]
Status Recruiting
Phase Phase 3
Start date October 6, 2021
Completion date October 6, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT04899180 - Prevalence of Transthyretin Cardiac Amyloidosis in Clinically Significant Aortic Stenosis Early Phase 1
Recruiting NCT04276220 - Prevalence of Wild-Type Transthyretin Cardiac Amyloidosis Among Patients Undergoing Carpal Tunnel Release Surgery - A Prospective Study N/A